Equities

Tong Ren Tang Technologies Co Ltd

Tong Ren Tang Technologies Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.31
  • Today's Change0.38 / 7.71%
  • Shares traded3.07m
  • 1 Year change-31.04%
  • Beta1.0114
Data delayed at least 15 minutes, as of Apr 26 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tong Ren Tang Technologies Co Ltd is a China-based company mainly engaged in the manufacture and sale of traditional Chinese medicine products. The Company's main businesses includes the production, retail and wholesale of traditional Chinese medicine products and health care products and the provision of traditional Chinese medicine diagnosis and treatment services. The Company is also engaged in the production, processing and acquisition of Chinese herbal medicines, drug sales, medical services and advertising. The Company mainly distributes its products in the domestic market and overseas markets.

  • Revenue in HKD (TTM)7.32bn
  • Net income in HKD637.89m
  • Incorporated2000
  • Employees4.10k
  • Location
    Tong Ren Tang Technologies Co LtdNo. 20 South Sanhuan Middle RoadFengtai DistrictBEIJING 100079ChinaCHN
  • Phone+86 1 087632888
  • Websitehttps://www.tongrentangkj.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alphamab Oncology236.45m-227.61m4.29bn435.00--2.38--18.16-0.2367-0.23670.24631.870.10280.770519.34543,573.90-9.90-18.72-11.69-21.9474.75---96.26-415.555.55--0.1333--31.12--35.35------
Jiangsu Recbio Technology Co Ltd0.00-618.18m4.41bn472.00--3.78-----1.29-1.290.002.420.00----0.00-25.47---30.68----------2.33--0.378------20.86------
Consun Pharmaceutical Group Ltd2.80bn847.94m4.64bn3.13k5.391.184.971.661.061.063.504.830.49812.089.10895,247.9015.1312.0422.5719.2574.1974.5530.3724.892.62--0.115541.5310.717.0314.8811.01--18.43
Ascentage Pharma Group International239.92m-1.00bn5.02bn583.00--76.88--20.93-3.53-3.530.84990.2250.08332.382.22411,533.60-34.73-44.93-52.82-57.0486.2487.68-417.02-976.101.42-15.030.9622--5.85100.76-4.84--2.82--
Sihuan Pharmaceutical Holdings Group Ltd2.01bn-58.38m5.04bn2.87k--1.05116,536.802.51-0.0063-0.00630.21630.51340.15720.86572.35700,174.90-2.18-6.85-3.34-9.1069.6475.81-13.85-36.231.37-0.51190.1863---14.70-8.6097.23------
Shandong Boan Biotechnology Co Ltd668.08m-129.02m5.04bn745.00--3.53--7.55-0.2533-0.25331.312.800.27321.352.53---5.28---7.02--66.16---19.31--0.8383-7.470.2352--19.80--64.02------
Beijing Luzhu Biotechnology Co Ltd0.00-269.50m5.26bn133.00--4.77-----1.35-1.350.005.45------0.00----------------6.41--0.0185------65.62------
Microport NeuroTech Ltd-100.00bn-100.00bn5.28bn571.00------------------------------------------------21.61--768.73------
ImmuneOnco Biopharmaceuticls Shanghi Inc-100.00bn-100.00bn5.59bn---------------------------------------------------28.25--5.82------
Shanghai Fudan-Zhangjiang Bio-Pharm. Co919.49m117.41m6.30bn948.0018.580.8624--6.850.11410.11410.87482.460.29071.811.79969,922.903.717.034.649.0591.0692.1712.7517.263.62151.720.007339.16-17.502.78-21.28-0.632620.490.00
Tong Ren Tang Technologies Co Ltd7.32bn637.89m6.31bn4.10k9.900.8484.610.86250.4980.4985.725.810.52120.98355.681,785,144.007.647.6812.1012.3242.0443.5014.6516.112.37--0.144339.9413.046.011.25-2.73-22.260.0178
New Horizon Health Ltd1.47bn119.56m6.47bn1.04k59.102.0041.574.400.23920.23923.227.050.45362.162.081,676,600.003.67--3.99--88.74--8.10--10.50--0.1305--259.54--97.40------
China Shineway Pharmaceutical Group Ltd4.88bn1.05bn7.73bn3.53k6.741.026.241.581.391.396.469.190.50731.446.31--10.898.0314.159.7775.1574.5521.4717.872.98--0.041145.7914.3211.9434.1413.89--12.88
Beijing Tong Ren Tang Chinese Medicine1.52bn540.39m7.77bn798.0014.382.0111.545.090.64560.64561.824.620.35220.64492.311,910,959.0013.6416.7115.5018.7568.6769.8838.7340.728.59--0.031768.87-11.910.1459-16.33-1.43-16.307.49
Lepu Biopharma Co Ltd243.56m-23.88m7.80bn429.00--8.0597.3532.02-0.0144-0.01440.14680.58420.09171.061.62567,748.90-1.23---1.91--87.45---13.45--0.72010.13920.4549--1,347.16--96.79------
Everest Medicines Ltd136.11m-912.71m7.81bn432.00--1.43--57.40-2.92-2.920.434816.820.02032.254.57315,068.20-13.63-30.52-15.06-33.1472.67---670.57-5,745.258.29--0.0979--884.46---241.50--4.65--
Data as of Apr 26 2024. Currency figures normalised to Tong Ren Tang Technologies Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

17.19%Per cent of shares held by top holders
HolderShares% Held
HHLR Advisors Ltd.as of 30 Jun 202347.66m7.58%
The Vanguard Group, Inc.as of 05 Apr 202425.04m3.98%
Dimensional Fund Advisors LPas of 04 Apr 202412.14m1.93%
BlackRock Fund Advisorsas of 04 Apr 20249.22m1.47%
UBS Asset Management (Hong Kong) Ltd.as of 29 Dec 20235.76m0.92%
BlackRock Advisors (UK) Ltd.as of 02 Apr 20242.79m0.44%
Mellon Investments Corp.as of 04 Apr 20241.84m0.29%
APG Asset Management NVas of 31 Dec 20221.47m0.23%
UBS SDIC Fund Management Co., Ltd.as of 31 Dec 20221.16m0.19%
SSgA Funds Management, Inc.as of 04 Apr 2024987.00k0.16%
More ▼
Data from 30 Jun 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.